| Literature DB >> 35106293 |
Tanzina Sharmin Nipun1, Tanzila Ismail Ema2, Md Abdur Rashid Mia3, Md Saddam Hossen4, Farzana Alam Arshe2, Shahlaa Zernaz Ahmed2, Afsana Masud2, Fatiha Faheem Taheya2, Arysha Alif Khan2, Fauzia Haque2, Salauddin Al Azad5, Md Al Hasibuzzaman6, Mohammad Tanbir2, Samin Anis7, Sharmin Akter8, Sabrina Jahan Mily9, Dipta Dey10.
Abstract
OBJECTIVE: This research aims to study the target specificity of selective bioactive compounds in complexing with the human angiotensin-converting enzyme (hACE2) receptor to impede the severe acute respiratory syndrome coronavirus 2 influx mechanism resulting in cardiac injury and depending on the receptor's active site properties and quantum tunneling.Entities:
Keywords: SARS-CoV-2; cardiac injury; drug design; hACE2 receptor; molecular dynamic; quantum tunneling; simulation; supramolecular docking
Year: 2021 PMID: 35106293 PMCID: PMC8757663 DOI: 10.5455/javar.2021.h544
Source DB: PubMed Journal: J Adv Vet Anim Res ISSN: 2311-7710
Figure 1.Illustration of all the optimized ligands and receptor macromolecule simultaneously. The hACE2 receptor (PDB ID: 1R4L) with its active site for complexing with the ligands (A); the drone-like structure refers to the main conformation of the pocket (A). Among the ligands serpentine (D) was the control and the others are the test ligands means – piperolactam A (B), apigenin (C), isovitexin (E), and quercetin (F).
Figure 2.Selection of different active sites of the hACE2 receptor protein considering the binding energy (Kcal/mol) and the number of the amino acids involved at the docking region.
Figure 3.Illustration of the protein tunnels along with the tunnel length (Å) and radius (Å) of each of the tunnels for allocating any ligand in the super docking position.
Complete QSAR and ADME/T physiochemical and pharmacokinetic profiling of selected ligands.
| Name of ligand and ID | Physiochemical properties | Pharmacokinetic criteria | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MoW | LogP | H-Ac | H-Do | NRB | BBB | NVL | DL | IA | TC | AT | LD50 | HT | MTD | |
| Serpentine (control) CID 73073 | 348.402 | 3.4052 | 5 | 0 | 1 | 0.257 | 0 | yes | 97.616 | 0.931 | No | 3.675 | yes | −0.219 |
| Apigenin CID 5280443 | 270.240 | 2.5768 | 5 | 3 | 1 | −0.734 | 0 | yes | 93.5 | 0.566 | No | 2.450 | no | 0.328 |
| Isovitexin CID 162350 | 432.381 | 0.0917 | 10 | 7 | 3 | −1.375 | 1 | no | 64.729 | 0.442 | No | 2.558 | no | 0.649 |
| Piperolactam A CID 3081016 | 265.268 | 3.2729 | 3 | 2 | 1 | −0.397 | 0 | yes | 95.084 | 0.046 | Yes | 2.634 | no | −0.128 |
| Quercetin CID 5280343 | 302.238 | 1.9880 | 7 | 5 | 1 | −1.098 | 0 | Yes | 77.207 | 0.407 | No | 2.471 | no | 0.499 |
QSAR, Quantitative structure–activity relationship; ADME/T, Absorption, distribution, metabolism, excretion, and toxicity; MoW, molecular weight, g/mol; LogP, Predicted octanol/water partition coefficient; H-Ac, No. of hydrogen bond acceptor; H-Do, No. of hydrogen bond donor; NRB, No. of rotatable bonds; BBB, Blood–Brain Barrier; NLV, No. of Lipinski’s rule violations; DL, Drug likeness; IA, Intestinal absorption, % absorbed; TC, Total clearance, log ml/min/kg; AT, AMES toxicity; LD50, Oral rat acute toxicity; HT, Hepatotoxicity; MTD, Maximum tolerated dose for human, log mg/kg/day.
NRB and NVL were taken from SwissADME and the rests from pkCSM.
Pharmacokinetics profiling of ADMET and QSAR for ligand validation.
| Macromolecule | Ligand | Binding affinity (Kcal/mol) | RMSD (Å) | |
|---|---|---|---|---|
| Upper Bound (Å) | Lower Bound (Å) | |||
|
| Serpentine (control) | -8.6 | 20.224 | 18.545 |
|
| Quercetin | -8.9 | 6.186 | 3.72 |
|
| Isovitexin | -9.9 | 8.951 | 5.004 |
|
| Piperolactam A | -8.6 | 4.847 | 2.351 |
|
| Apigenin | -8.1 | 17.556 | 17.187 |
RMSD, Root mean square deviation; UB, Upper bound; LB, Lower bound;
1R4L was taken as standard macromolecules for hydrolyzing lignin and cellulose, respectively; PubChem CID: serpentine (73391), quercetin (5280343), isovitexin (162350), piperolactam A (3081016), apigenin (5280443).
Figure 4.Identification of the super docking position of the control ligand (serpentine) inside the hACE2 receptor as well as the hydrogen and hydrophobic interactions involvement inside the ‘serpentine–hACE2 receptor’ complex. The distances among the amino acid residues are mentioned using red lines where the hydrogen bonds are the pink lines (A) as 3D confirmation. Besides, the most stable hydrogen bonds (green line) and hydrophobic interactions (red lines) are represented in 2D.
Figure 5.The super docking positions of the test ligands are portraited when complexed with the hACE2 macromolecule. The formation of hydrogen bonds and hydrophobic interactions are mentioned using pink and red lines, respectively. The complexes are apigenin–1R4L (A), isovitexin–1R4L (B), piperolactam A–1R4L, (C), and quercetin–1R4L (D).
Analysis of the binding affinities of the candidate ligands with the hACE2 receptor
| Macromolecule | Ligand | Amino acid involved interactions | |
|---|---|---|---|
| Hydrogen bond interactions | Hydrophobic bond interactions | ||
|
| Serpentine | Arg518(2.92 Å) | Thr445, Phe274, Asp367, His374, Thr371 |
| Quercetin | Arg518(2.89 Å), Glu406(2.97 Å), Pro (2.87 Å) | Asp367, Phe274, Thr371, Glu375, His374 | |
| Isovitexin | Thr371(3.25 Å), Asp367(2.82 Å), Glu406(3.12 Å), Arg (2.82 Å) | Phe274, Glu375, Pro346, His345, Thr347, His374, Tyr515, Glu402 | |
| Piperolactam A | Arg518(3.02 Å), Thr(3.10 Å) | Glu406, Phe274, Thr276 | |
| Apigenin | Glu402(2.87 Å), His374(3.08 Å), Pro346(2.73 Å), Thr445(2.57 Å) | Glu375, Thr371, Phe274, Tyr515 | |
Figure 6.Identification of the ligand–receptor stabilities following the number of hydrogen bonds (green lines) and the noncovalent interactions (red lines) among the ligand and the amino acid residues. hACE2 receptor protein is complexed with piperolactam A (A) apigenin (B), isovitexin (C), quercetin (D).
Figure 7.Molecular dynamic simulation (20 ns runtime) of the ligand–receptor complexes’ results, means – RMSD (A), RMSF (B), H-bonds (C), Cα (D), SASA (E), MolSA (F), Rg (G), and PSA (H).
Solvent accessible surface area (Å2) referring the area to energy ratio over the entire dynamic simulation process (100 ns) with polar and apolar regions precisely
| Macromolecule | Ligand | Water Probe Radius ( Å ) | Gradient in Calculation | Total number of Residue | Total area/Energy | ||
|---|---|---|---|---|---|---|---|
| Polar | Apolar | Unknown | |||||
| 1R4L | Serpentine | 1.400 | No | 597 | 9598.23 | 14050.71 | 0.00 |
| 1R4L | Quercetin | 1.400 | No | 597 | 9598.23 | 14050.71 | 0.00 |
| 1R4L | Isovitexin | 1.400 | No | 597 | 9598.23 | 14050.71 | 0.00 |
| 1R4L | Piperolactam A | 1.400 | No | 597 | 9598.23 | 14050.71 | 0.00 |
| 1R4L | Apigenin | 1.400 | No | 597 | 9598.23 | 14050.71 | 0.00 |
WPR, Water probe radius; GIC, Gradient in calculation; TNR, Total no. of residues.